Abstract:CDK4/6 inhibitors have proven effective in treating HR+/HER2- breast cancer, but their limited therapeutic indications and the emergence of acquired resistance are concerning. Recent studies suggest that hematological toxicity linked to CDK4/6 dual inhibitors may be due to strong CDK6 inhibition. To address these challenges, small molecules targeting different CDK subfamily members could provide clinical advantages in specific patient subgroups and expand CDK inhibitor indications beyond breast cancer. However, the high conservation of CDK's binding pocket makes designing molecules selectively targeting different CDKs challenging. In this study, we use in-depth in silico modeling and structural biology analysis of co-crystal data to analyze subtle variations in several CDKs' key binding pockets. Our findings indicate that a sequential difference of a αD-helix motif between CDK4 and CDK6 represents an ideal "sweet spot" that influences binding selectivity. To achieve this selectivity, we designed small molecules with a 1,4-trans-cyclohexanediamine sidechain that specifically promotes interactions with the αD-helix motif in CDK4 but not in CDK6. Interestingly, the same αD-helix motif in CDK9 presented an opportunity to develop a CDK4/9 inhibitor, potentially improving acquired resistance to CDK4/6 inhibitors. Our rational approach identified a series of analogs exhibiting distinct in vitro selectivity among CDK4, CDK6, and CDK9. The lead compound (29) was further evaluated for in vivo pharmacokinetics. This work revealed key molecular insights for developing next-generation CDK inhibitors with unique selectivity profiles. This approach could help overcome the challenges of developing selective CDK inhibitors and broaden their therapeutic indications beyond breast cancer.

Discovery of Novel and Potent Tacrine Derivatives as CDK2 Inhibitors

Discovery of novel tacrine derivatives as potent antiproliferative agents with CDKs inhibitory property

Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors

Discovery and optimization of thieno[3,2- d ]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7

Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors

Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2

Design, Synthesis and Biological Evaluation of Pteridine-7(8H)-one Derivatives As Potent and Selective CDK4/6 Inhibitors

Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors

Discovery of a Novel Macrocyclic Noncovalent CDK7 Inhibitor for Cancer Therapy

Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2h-pyran-4-carbonitrile (JSH-150) As a Novel Highly Selective and Potent CDK9 Kinase Inhibitor.

Discovery and SARs of 5-Chloro-n4-phenyl-n2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives As Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Synthesis and Structure-Activity Relationships of Cyclin-Dependent Kinase 11 Inhibitors Based on a Diaminothiazole Scaffold

Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate

Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors

Design, Synthesis and Biological Evaluation of Thienopyridinones As Chk1 Inhibitors

Elucidating Binding Selectivity in Cyclin-Dependent Kinases (CDKs) 4, 6, and 9: Development of Highly Potent and Selective CDK4/9 Inhibitors

Molecular Principle of the Cyclin-Dependent Kinase Selectivity of 4-(Thiazol-5-yl)-2-(phenylamino) Pyrimidine-5-carbonitrile Derivatives Revealed by Molecular Modeling Studies.

Discovery of the Novel 1 H -Pyrrolo[2,3- b ]pyridine Derivative as a Potent Type II CDK8 Inhibitor against Colorectal Cancer

Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer

Structure-Based Drug Design, Synthesis and Antitumor Activities of Novel CDK7 Inhibitors

Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities